You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Merck
McKinsey
Baxter
AstraZeneca
Dow

Last Updated: June 6, 2020

DrugPatentWatch Database Preview

Ranbaxy Company Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for RANBAXY, and when can generic versions of RANBAXY drugs launch?

RANBAXY has forty-five approved drugs.

There is one US patent protecting RANBAXY drugs. There are fifteen tentative approvals on RANBAXY drugs.

There are eighteen patent family members on RANBAXY drugs in eighteen countries and sixty-seven supplementary protection certificates in fifteen countries.

Summary for Ranbaxy

Drugs and US Patents for Ranbaxy

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ranbaxy DOXYCYCLINE HYCLATE doxycycline hyclate CAPSULE;ORAL 062479-002 Dec 23, 1983 DISCN No No   Start Trial   Start Trial
Ranbaxy Labs Ltd TERAZOSIN HYDROCHLORIDE terazosin hydrochloride CAPSULE;ORAL 076021-001 Aug 22, 2002 DISCN No No   Start Trial   Start Trial
Ranbaxy Labs Ltd CEFUROXIME AXETIL cefuroxime axetil TABLET;ORAL 065043-003 Feb 15, 2002 DISCN No No   Start Trial   Start Trial
Ranbaxy RANITIDINE HYDROCHLORIDE ranitidine hydrochloride TABLET;ORAL 075254-001 Jan 14, 2000 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Ranbaxy Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0206283 98C0041 Belgium   Start Trial PRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606
0809498 10C0038 France   Start Trial PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
1506211 C01506211/02 Switzerland   Start Trial PRODUCT NAME: DAPAGLIFLOZIN + METFORMIN; REGISTRATION NO/DATE: SWISSMEDIC 65377 16.07.2015
1506211 PA2014026 Lithuania   Start Trial PRODUCT NAME: DAPAGLIFOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
AstraZeneca
Medtronic
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.